Related Experiment Videos
New drug interactions with zidovudine
S Robertson-Dallas1, S E Read, R Bendayan
1Faculty of Pharmacy, University of Toronto, Ontario, Canada.
Pharmacotherapy
|December 17, 1997
Summary
Human immunodeficiency virus (HIV)-positive patients often take multiple medications, increasing the risk of drug interactions. Zidovudine (ZDV), a key HIV drug, has known interactions, with more expected as HIV treatment advances.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Pharmacy
Background:
- Polypharmacy is prevalent in human immunodeficiency virus (HIV)-positive patients.
- The risk and frequency of drug-drug interactions (DDIs) are significant concerns in this population.
- Zidovudine (3'-azido-3'-deoxythymidine, ZDV) is a foundational antiretroviral therapy for HIV.
Purpose of the Study:
- To highlight the significance of drug-drug interactions in HIV-positive patients.
- To underscore the importance of understanding ZDV interactions.
- To anticipate the increasing potential for DDIs with evolving HIV pharmacotherapy.
Main Methods:
- Review of existing literature on drug interactions with zidovudine (ZDV).
- Analysis of polypharmacy trends in HIV-positive patient populations.
- Assessment of the impact of complex HIV pharmacotherapy on DDI risk.
Main Results:
- Numerous drug interactions involving ZDV have been documented.
- Polypharmacy in HIV patients presents a substantial challenge for safe medication management.
- The complexity of modern HIV treatment regimens increases the likelihood of DDIs.
Conclusions:
- Managing drug-drug interactions is critical for the safe and effective treatment of HIV.
- Continued vigilance and research are necessary to address the growing challenge of DDIs in HIV pharmacotherapy.
- Healthcare providers must be aware of potential interactions, especially with zidovudine (ZDV).